In the past two decades, quantitative PET has become a necessity
in clinical oncology. Despite introduction of various measures for quantification and correction of PET parameters, there is debate on the selection of the appropriate methodology in specific diseases and conditions. In this review, we have focused on these techniques with special attention to topics such as static and dynamic whole body PET imaging, tracer kinetic modeling, global disease burden, texture analysis and radiomics, dual time point imaging and partial volume correction. Eivind A. Segtnan, Søren Hess, Peter Grupe, and Poul Flemming Høilund-Carlsen Structural imaging with computed tomography (CT) and MR imaging is the mainstay in primary diagnosis of primary brain tumors, but these modalities depend
on morphologic appearance and an intact blood-brain barrier, and Sirolimus molecular weight important aspects of tumor biology are not addressed. Such issues may be alleviated by 18F-fluorodeoxyglucose (FDG)-PET and FDG-PET/CT imaging, which may provide clinically important information with regard to primary differentiation between tumor types, initial staging and risk stratification, therapy planning, response evaluation, and recurrence detection. This article describes some of the potential contemporary applications of FDG and PET in primary brain tumors. Jeppe Kiilerich Lauridsen, Max Rohde, and Anders Thomassen 18F-fluorodeoxyglucose Obatoclax Mesylate (GX15-070) positron emission tomography/computed tomography (FDG-PET/CT) is a valuable diagnostic tool in a spectrum of PLX4032 manufacturer malignant and benign conditions, because of a high sensitivity to detect even very small lesions with increased metabolism. This review focuses on the use of FDG-PET/CT in malignancies of the thyroid gland and in head and neck squamous cell carcinoma. Malene Grubbe Hildebrandt, Annette
Raskov Kodahl, Dorte Teilmann-Jørgensen, Ole Mogensen, and Pernille Tine Jensen In this literature review, an update is provided on the role of [18F]fluorodeoxyglucose PET/computed tomography in different clinical settings of the 4 most frequent female-specific cancer types: breast, endometrial, ovarian, and cervical cancer. The most recent knowledge regarding primary diagnosis, staging, response evaluation, prognostic and predictive values, recurrence detection, and radiotherapy planning is evaluated, including, when clinically relevant, considerations with respect to the epidemiology, treatment, and course of the diseases. Oke Gerke, Ronnie Hermansson, Søren Hess, Søren Schifter, Werner Vach, and Poul Flemming Høilund-Carlsen The development of clinical diagnostic procedures comprises early-phase and late-phase studies to elucidate diagnostic accuracy and patient outcome.